

Contents

	Introduction	21
	History of brachytherapy	22
	Physical aspects – sources, dosimetry and dose specification	28
3.1.	Sources.....	28
3.1.1.	Radionuclides in brachytherapy	28
3.1.1.1.	Gamma and characteristic X-ray radiation	28
3.1.1.2.	Beta-emitters.....	29
3.1.2.	Characterisation of source strength	29
3.2.	Dosimetry	29
3.2.1.	Control of reference air kerma rate.....	29
3.2.1.1.	Measurement with well-type ionisation chambers.....	29
3.2.1.2.	Measurement in compact chambers in solid body phantoms	29
3.2.2.	Checking the source position	30
3.2.3.	Calculation of dose distributions.....	30
3.2.3.1.	Dose distributions of single sources.....	30
3.2.3.2.	Applicator reconstruction.....	31
3.2.4.	Optimisation and visualisation of dose distributions.....	33
	Quality assurance	38
4.1.	Quality assurance for afterloading devices and procedures in case of emergency for a remote afterloader.....	38
4.2.	Quality assurance in brachytherapy treatment planning systems	41
4.3.	Special methods	41
	Dosimetrical aspects – dose specifications, dose-volume definitions, EQD2 concept	46
5.1.	Dose specification in general.....	46
5.2.	Dose specification in intraluminal and intracavitary therapy.....	47
5.2.1.	Source positions along one straight line (e.g. vaginal cylinder, oesophageal/bronchial applicators, vessels)	47
5.2.2.	Advanced cervical carcinoma.....	48
5.2.3.	Endometrial carcinoma not treated surgically	48
5.3.	Dose specification in interstitial brachytherapy	48
5.3.1.	Point based systems.....	48
5.3.2.	Dose and volume relations, Dose-volume histograms (DVH) and quality parameters (indices)	50
5.3.2.1.	Relevant dose values and volumes	50
5.3.2.2.	Quality parameters – QI indices	51
5.4.	Dose fractionation, combination with external beam and the EQD2 concept.....	53
	Clinical treatment planning and imaging	56
6.1.	Clinical treatment planning	56
6.1.1.	Indication.....	56
6.1.1.1.	Definitive treatment.....	56
6.1.1.2.	Adjuvant therapy.....	56

6.1.2.	Gross Target Volume (GTV) and Clinical Target Volume (CTV)	56
6.1.3.	Selection of technique, preliminary and definitive treatment plan.	57
6.1.3.1.	Interstitial brachytherapy	57
6.1.3.2.	Intracavitary brachytherapy	60
6.1.3.3.	Intraluminal brachytherapy	60
6.1.4.	Dose, dose fractionation, dose rate.	60
6.1.5.	Infrastructure and personnel planning	61
6.2.	Modern imaging techniques in brachytherapy	62
6.2.1.	Basics of image-guided brachytherapy	62
6.2.2.	Image-guided preliminary treatment planning	64
6.2.3.	Image-guided application	64
6.2.4.	Image-guided definitive treatment planning	65
6.2.5.	Imaging techniques in brachytherapy	66
6.2.5.1.	CT imaging	66
6.2.5.2.	MR imaging	67
6.2.5.3.	US imaging	67

Instruments and equipment

69

7.1.	Instruments for interstitial brachytherapy	69
7.1.1.	Temporary implants	69
7.1.1.1.	Needles, catheters	69
7.1.1.2.	Templates	71
7.1.1.3.	Auxiliary instruments	73
7.1.2.	Permanent implants	74
7.2.	Instruments for intracavitary brachytherapy	75
7.2.1.	Uterovaginal applicators	75
7.2.2.	Vaginal applicators	76
7.2.3.	Endometrial applicators	77
7.2.4.	Intraluminal applicators for tumours in the oesophagus, bronchus, trachea, common bile duct and nasopharynx and for intravascular brachytherapy	77
7.2.5.	Moulds for cancers of the paranasal sinuses or orbit	78
7.3.	Surface applicators	78
7.3.1.	Skin applicators	78
7.3.2.	Eye applicators	79
7.4.	Afterloading devices	79
7.4.1.	The irradiation device	80
7.4.2.	The control unit	81
7.4.3.	Important requirements for radiation protection	81

Intra- and perioperative brachytherapy

82

8.1.	Introduction	82
8.2.	Indications and patient selection criteria	83
8.2.1.	Intraoperative brachytherapy	83
8.2.2.	Perioperative brachytherapy	84
8.3.	Practical execution and technique, practical tips	85
8.4.	Treatment planning	87
8.4.1.	Target volumes, dose specification and dose, QA	87
8.5.	Results	88

8.6.	Side effects	89
8.6.1.	Short-term toxicity	89
8.6.2.	Long-term toxicity	89
8.7.	Summary	90

Interstitial hyperthermia 91

9.1.	Techniques of interstitial hyperthermia	91
9.2.	Planning, performance and documentation of interstitial hyperthermia	91
9.3.	Quality and effectiveness of hyperthermia	92
9.4.	Treatment results in interstitial brachytherapy and hyperthermia	92
9.4.1.	Glioblastoma	92
9.4.2.	Local and locoregional recurrences of head and neck cancer	93
9.4.3.	Breast cancer	94
9.4.4.	Tumours of the small pelvis	94
9.4.5.	Prostate cancer	94
9.6.	Summary	95

Pre- and postoperative supportive care in brachytherapy 97

10.1.	Patient preparation	97
10.2.	Anaesthesia and patient positioning	97
10.3.	Pain management	98
10.4.	Anti-infective therapy	98
10.5.	Prophylaxis of thrombosis	99
10.6.	Pre- and postoperative supportive care by specific tumour sites	99
10.6.1.	Head and neck cancer	99
10.6.2.	Breast cancer	100
10.6.3.	Prostate cancer	100
10.6.4.	Gynaecological tumours	101
10.7.	Follow-up	102

Cervical cancer 103

11.1.	Indications	103
11.2.	Brachytherapy pre-planning	103
11.2.1.	Brachytherapy target volumes	103
11.2.2.	Organs at risk	105
11.2.3.	Dose optimisation	105
11.2.4.	Dose, dose rate, fractionation	112
11.3.	Technique of applicator insertion	112
11.4.	Results	113
11.4.1.	Concomitant chemoradiotherapy	113
11.5.	Side effects	114
11.6.	Summary	114

Endometrial carcinoma 117

12.1.	Indications, patient selection criteria	117
12.1.1.	Current Indications for adjuvant radiotherapy, including Brachytherapy	117
12.1.1.1.	Low risk endometrial cancer	117
12.1.1.2.	Intermediate risk endometrial cancer	117

12.1.1.3.	High to intermediate risk endometrial cancer	118
12.1.1.4.	High risk endometrial cancer	118
12.1.1.5.	Adjuvant intravaginal brachytherapy	119
12.1.2.	Brachytherapy in primary endometrial carcinoma	119
12.1.3.	Intracavitary and interstitial brachytherapy for recurrences	119
12.2.	Treatment planning	120
12.2.1.	Target volumes	120
12.2.1.1.	Adjuvant intracavitary brachytherapy	120
12.2.1.2.	Primary brachytherapy	121
12.2.1.3.	Interstitial brachytherapy in recurrent disease	122
12.2.2.	Dose specification	122
12.2.2.1.	Adjuvant brachytherapy	122
12.2.2.2.	Primary brachytherapy	123
12.2.2.3.	Interstitial brachytherapy	123
12.2.3.	Dose, dose rate, fractionation	123
12.3.	Practical execution and technique	124
12.3.1.	Adjuvant brachytherapy	124
12.3.2.	Primary brachytherapy	124
12.3.3.	Interstitial brachytherapy	124
12.4.	Results	125
12.5.	Side effects	125
12.6.	Summary	126

Primary vaginal carcinoma 128

13.1.	Indications	128
13.2.	Brachytherapy pre-planning	128
13.2.1.	Target volume	128
13.2.2.	Organs at risk	130
13.2.3.	Dose planning	130
13.2.4.	Dose, dose rate and fractionation	131
13.2.4.1.	Planning aims for the target volumes	131
13.2.4.2.	Dose constraints for the organs at risk	132
13.3.	Practical execution and technique	132
13.4.	Results	133
13.5.	Side effects	133
13.6.	Summary	134

Vulvar carcinoma 135

14.1.	Indications, patient selection criteria	136
14.2.	Treatment planning	136
14.2.1.	Target volumes	136
14.2.2.	Dose specification	137
14.2.3.	Dose, dose rate, fractionation	138
14.3.	Practical execution and technique	138
14.4.	Results	140
14.5.	Side effects	140
14.6.	Summary	141

Carcinoma of the female urethra 142

15.1.	Indications, patient selection criteria	142
15.2.	Treatment planning	142
15.2.1.	Target volumes	142
15.2.2.	Dose specification.	142
15.2.3.	Dose, dose rate, fractionation.	143
15.3.	Practical execution and technique.	143
15.4.	Results	144
15.5.	Side effects	144
15.6.	Summary.	145

Carcinoma of the prostate 146

16.1.	Indications, patient selection criteria	147
16.1.1.	Permanent brachytherapy with J-125 seeds	147
16.1.2.	Temporary brachytherapy with Ir-192.	147
16.1.3.	Contraindications to brachytherapy	147
16.2.	Treatment planning	147
16.2.1.	Target volumes and organs at risk	147
16.2.2.	Isotope, dose specification and fractionation.	148
16.2.2.1.	Permanent brachytherapy with J-125 , Pd-103	148
16.2.2.2.	Temporary brachytherapy with Ir-192.	148
16.3.	Practical execution and technique.	149
16.3.1.	Permanent brachytherapy (seeds)	150
16.3.2.	Temporary brachytherapy	151
16.4.	Results	154
16.4.1.	Permanent brachytherapy (seeds)	154
16.4.2.	Temporary brachytherapy (HDR)	154
16.4.3.	Salvage brachytherapy as re-irradiation.	155
16.5.	Side effects	155
16.5.1.	Permanent brachytherapy (seeds)	155
16.5.2.	Temporary brachytherapy (HDR)	155
16.6.	Summary.	156

Carcinoma of the penis 159

17.1.	Indications, patient selection criteria	159
17.2.	Treatment planning	159
17.3.	Practical execution and technique.	159
17.3.1.	Surface mould brachytherapy	159
17.3.2.	Interstitial brachytherapy.	160
17.4.	Results	163
17.5.	Side effects	163
17.5.1.	Early side effects	163
17.5.2.	Late side effects.	163
17.6.	Summary.	164

Bladder cancer 165

18.1.	Indications	165
18.2.	Treatment planning	165

18.3.	Dose specification	166
18.4.	Dose, dose rate and fractionation	167
18.5.	Practical execution and technique	167
18.6.	Results	167
18.7.	Side effects	168
18.8.	Summary	168

Head and neck tumours

170

19.1.	Carcinoma of the lip	170
19.1.1.	Indications, patient selection criteria	170
19.1.2.	Treatment planning	170
19.1.2.1.	Target volumes	170
19.1.2.2.	Dose specification	170
19.1.2.3.	Dose, dose rate, fractionation	172
19.1.3.	Practical execution, technique	172
19.1.4.	Results	172
19.1.5.	Side effects	172
19.2.	Oral cavity: carcinoma of the floor of the mouth, carcinoma of the mobile tongue	172
19.2.1.	Indications, patient selection criteria	172
19.2.2.	Treatment planning	174
19.2.2.1.	Target volumes	174
19.2.2.2.	Dose specification	175
19.2.2.3.	Dose, dose rate, fractionation	175
19.2.3.	Practical execution, technique	175
19.2.4.	Results	177
19.2.5.	Side effects	178
19.3.	Oropharynx	178
19.3.1.	Indications, patient selection criteria	178
19.3.2.	Treatment planning	178
19.3.2.1.	Target volumes	178
19.3.2.2.	Dose specification	178
19.3.2.3.	Dose, dose rate, fractionation	178
19.3.3.	Practical execution, technique	179
19.3.4.	Results	182
19.3.5.	Complications	182
19.4.	Buccal mucosa	182
19.4.1.	Indications, patient selection criteria	182
19.4.2.	Treatment planning	182
19.4.2.1.	Target volumes	182
19.4.2.2.	Dose specification	182
19.4.2.3.	Dose, dose rate, fractionation	182
19.4.3.	Practical execution and technique	183
19.4.4.	Results	183
19.4.5.	Side effects	183
19.5.	Nasopharynx	183
19.5.1.	Indications, patient selection criteria	183
19.5.2.	Treatment planning	183
19.5.2.1.	Target volumes	183
19.5.2.2.	Dose specification	183
19.5.2.3.	Dose, dose rate, fractionation	183
19.5.3.	Practical execution, technique	184

19.5.4.	Results.....	184
19.5.5.	Side effects	186
19.6.	Nasal cancer.....	186
19.6.1.	Indications, patient selection criteria.....	186
19.6.2.	Treatment planning.....	186
19.6.2.1.	Target volumes	186
19.6.2.2.	Dose specification.....	186
19.6.2.3.	Dose, dose rate, fractionation.....	186
19.6.3.	Practical execution, technique.....	186
19.6.4.	Results.....	188
19.6.5.	Side effects	188
19.7.	Summary.....	188

Breast cancer

191

20.1.	Indications, patient selection criteria	191
20.1.1.	Interstitial brachytherapy as boost.....	191
20.1.2.	Partial breast irradiation with interstitial multicatheter brachytherapy alone	191
20.1.3.	Postoperative surface/interstitial brachytherapy of the chest wall after chest wall recurrence in patients who have previously had radiotherapy.....	193
20.2.	Treatment planning	193
20.2.1.	Target volumes	193
20.2.1.1.	Interstitial brachytherapy.....	193
20.2.1.2.	Target volume in surface brachytherapy	199
20.2.1.3.	Target volume in interstitial brachytherapy for the chest wall	199
20.2.2.	Dose specification.....	199
20.2.2.1.	Interstitial brachytherapy.....	199
20.2.2.2.	Surface brachytherapy	200
20.2.2.3.	Interstitial brachytherapy chest wall	200
20.2.3.	Dose, dose rate, fractionation.....	200
20.3.	Practical execution and technique.....	201
20.3.1.	Interstitial brachytherapy.....	201
20.3.2.	Mould (surface brachytherapy)	204
20.3.3.	Interstitial brachytherapy of the chest wall	204
20.4.	Results	204
20.4.1.	Boost	204
20.4.2.	Interstitial brachytherapy alone.....	205
20.4.3.	Surface radiotherapy of the chest wall as re-irradiation	205
20.5.	Side effects	205
20.5.1.	Boost	206
20.5.2.	Interstitial brachytherapy alone as APBI.....	206
20.5.3.	Surface salvage-brachytherapy as re-irradiation	206
20.6.	Summary.....	206

Lung cancer

210

21.1.	Indications, patient selection criteria	210
21.1.1.	Curative endobronchial brachytherapy	210
21.1.2.	Palliative endobronchial brachytherapy.....	211
21.1.3.	Curative endobronchial brachytherapy combined with external beam radiotherapy	211
21.1.4.	Palliative endobronchial brachytherapy in combination with external beam radiotherapy.....	211

21.2.	Treatment planning	212
21.2.1.	Target volumes	212
21.2.1.1.	The target volume for a curative intention	212
21.2.1.2.	The target volume for a palliative intention	212
21.2.2.	Dose specification.....	212
21.2.2.1.	The dose specification for a curative intention.....	212
21.2.2.2.	The dose specification for a palliative intention.....	213
21.2.3.	Dose, dose rate, fractionation.....	213
21.3.	Practical execution and technique.....	214
21.4.	Results	215
21.4.1.	Results of endobronchial HDR or LDR brachytherapy alone in curative intention	215
21.4.2.	Results of combined external beam and endobronchial radiotherapy in curative intention	215
21.4.3.	Results of endobronchial HDR or LDR brachytherapy alone in palliative intention	215
21.4.4.	Results of combined external beam and endobronchial radiotherapy in palliative intention	216
21.5.	Side effects	216
21.6.	Interstitial and intraoperative brachytherapy – indication, technique, results	218
21.7.	Summary.....	219

Oesophageal carcinoma

222

22.1.	Indications, patient selection.....	222
22.2.	Treatment planning	222
22.2.1.	Target volumes	222
22.2.2.	Dose specification.....	224
22.2.3.	Dose, dose rate, fractionation.....	225
22.3.	Practical execution and technique.....	225
22.4.	Results	226
22.5.	Side effects.....	227
22.6.	Summary.....	228

Carcinoma of the anal canal

230

23.1.	Indications, patient selection criteria	230
23.2.	Treatment planning	230
23.2.1.	Target volumes	231
23.2.2.	Dose specification.....	231
23.2.3.	Dose, dose rate, fractionation.....	231
23.3.	Practical execution and technique.....	232
23.4.	Results and side effects	233
23.5.	Side effects.....	234
23.6.	Summary.....	235

Skin tumours

237

24.1.	Indications, patient selection criteria	237
24.2.	Treatment planning	237
24.2.1.	Target volumes	238
24.2.2.	Dose specification.....	238
24.2.3.	Dose, dose rate, fractionation.....	238
24.3.	Practical execution and technique.....	238
24.4.	Results	241

24.5.	Side effects	242
24.6.	Summary	242

Uveal choroidal melanomas 244

25.1.	Indications, patient selection criteria	244
25.2.	Treatment planning	244
25.2.1.	Target volumes	244
25.2.2.	Eye plaques	245
25.2.2.1.	Ruthenium-106 eye plaques	245
25.2.2.2.	Iodine-125 eye plaques	245
25.2.3.	Dose specification and dosimetry	246
25.2.3.1.	Ruthenium-106 eye plaques	246
25.2.3.2.	Iodine-125 eye plaques	247
25.3.	Practical execution and technique	247
25.4.	Results	249
25.5.	Side effects	251
25.6.	Summary	251

Paediatric malignancies 253

26.1.	Indications	253
26.2.	Treatment planning	253
26.2.1.	Target volumes	253
26.2.2.	Dose specification	253
26.2.3.	Dose, dose rate, fractionation	253
26.3.	Practical execution and technique	253
26.4.	Results	255
26.5.	Side effects	256
26.6.	Summary	256

Primary and secondary liver malignancies 257

27.1.	Indication, patient selection criteria	257
27.2.	Practical execution and technique	257
27.3.	Treatment planning	259
27.4.	Results	262
27.5.	Summary	263

Soft tissue sarcomas 266

28.1.	Indications, patient selection criteria	266
28.2.	Treatment planning	266
28.2.1.	Target volumes	266
28.2.2.	Dose specification	266
28.2.3.	Dose, dose rate, fractionation	266
28.3.	Practical execution and technique	266
28.4.	Results	267
28.5.	Side effects	269
28.6.	Summary	269

	Keloids and pterygia	275
29.1.	Indications, patient selection criteria	275
29.2.	Treatment planning	275
29.2.1.	Target volumes	275
29.2.2.	Dose specification.....	275
29.2.3.	Dose, dose rate, fractionation.....	275
29.3.	Practical execution and technique.....	276
29.4.	Results	278
29.5.	Side effects.....	278
29.6.	Summary.....	279
	Perspectives in brachytherapy	281
30.1.	Summary.....	283
	Index	284